Name: Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples (Video) | JoVE Journal
Uploaded: 2020-10-02T14:00:00.000+00:00
Duration: 7 min 3 s
Description: Learn to isolate breast cancer stem cells from cell and tissue samples with high purity and viability. This protocol enables in vitro and in vivo functional assays to study tumorigenicity and metastasis.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

We thank members of our laboratory for their helpful discussions and support. Our research on breast cancer stem cells and the tumor microenvironment is funded by grants from the Canadian Cancer Research Society Research Institute and the U.S. Army Department of Defense Breast Cancer Program (Grant # BC160912). V.B. is supported by a Western Postdoctoral Fellowship (Western University), and both A.L.A. and V.B. are supported by the Breast Cancer Society of Canada. C.L. is supported by a Vanier Canada Graduate Scholarship from the Government of Canada.

The authors have nothing to disclose.

Breast cancer metastasis and resistance to therapy have become major cause of mortality in women worldwide. The existence of a sub-population of breast cancer stem cells (BCSCs) contributes to enhanced metastasis26,43,44,45,46 and therapy resistance21,47,48. Therefore...

Understanding the cellular and molecular mechanisms of human breast cancer stem cells (BCSCs) is crucial for addressing the challenges encountered in breast cancer treatment. The emergence of the BCSC concept dates back to the early 21st century, where a small population of CD44+CD24-/low breast cancer cells were found to be capable of generating heterogenous tumors in mice1,2. Subsequently, it was observed that human breast cancer cells with high enzymatic activity of aldehyde dehydrogenase (ALDHhigh) also displayed similar stem cell-like properties3. These BCSCs represent a small population of cells capable of self-renewal and differentiation, contributing to the heterogenous nature of bulk tumors1,2,3. Accumulating evidence suggest that alterations in evolutionarily conserved signaling pathways drive BCSC survival and maintenance4,5,6,7,8,9,10,11,12,13,14. In addition, the cell extrinsic microenvironment has been shown to play a pivotal role in dictating different BCSC functions15,16,17. These molecular pathways and the external factors regulating BCSC function contribute to breast cancer relapse, metastasis18 and development of resistance to therapies19,20,21, with the residual existence of BCSCs post-treatment posing a major challenge to the overall survival of breast cancer patients22,23. Pre-clinical evaluation of these factors is therefore very important for identifying BCSC-targeting therapies that could be beneficial for achieving better treatment outcomes and improved overall survival in breast cancer patients.
Several in vitro human breast cancer cell line models and in vivo human xenograft models have been used to characterize BCSCs24,25,26,27,28,29. The ability of cell lines to continuously repopulate after every successive passage makes these an ideal model system to perform omics-based and pharmacogenomic studies. However, cell lines often fail to recapitulate the heterogeneity observed in patient samples. Hence, it is important to complement cell line data with patient-derived samples. Isolation of BCSCs in their purest form is important for enabling detailed characterization of BCSCs. Achieving this purity depends on the selection of phenotypic markers that are specific to BCSCs. Currently, the ALDHhighCD44+CD24- cell phenotype is most commonly used to distinguish and isolate human BCSCs from bulk breast cancer cell populations using fluorescence activated cell sorting (FACS) for maximum purity1,3,26. Furthermore, the properties of isolated BCSCs such as self-renewal, proliferation, and differentiation can be evaluated using in vitro and in vivo techniques.
For example, in vitro colony forming assays can be used to assess the ability of a single cell to self-renew to form a colony of 50 cells or more in presence of different treatment conditions30. Mammosphere assays can also be used to assess the self-renewal potential of breast cancer cells under anchorage-independent conditions. This assay measures the ability of single cells to generate and grow as spheres (mixture of BCSCs and non-BCSCs) at each successive passage in serum-free non-adherent culture conditions31. Additionally, 3-Dimensional (3D) culture models can be used to assess BCSC function, including cell-cell and cell-matrix interactions that closely recapitulate the in vivo microenvironment and allow investigation of the activity of potential BCSC-targeted therapies32. Despite the diverse applications of in vitro models, it is difficult to model the complexity of in vivo conditions using only in vitro assays. This challenge can be overcome by use of mouse xenograft models to evaluate BCSC behavior in vivo. In particular, such models serve as an ideal system for assessing breast cancer metastasis33, investigating interactions with the microenvironment during disease progression34, in vivo imaging35, and for predicting patient-specific toxicity and efficacy of antitumor agents34.
This protocol provides a detailed description for the isolation of human ALDHhighCD44+CD24- BCSCs at maximum purity from bulk populations of heterogenous breast cancer cells. We also provide a detailed description of three in vitro techniques (colony forming assay, mammosphere assay, and 3D culture model) and an in vivo tumor xenograft assay that can be used to assess different functions of BCSCs. These methods would be appropriate for use by investigators interested in isolating and characterizing BCSCs from human breast cancer cell lines or primary-patient derived breast cancer cells and tumor tissue for the purposes of understanding BCSC biology and/or investigating novel BCSC-targeting therapies.

<table><tbody><tr><td>7-Aminoactinomycin D (7AAD)</td><td>BD</td><td>51-68981E</td><td>suggested: 0.25 &amp;micro;g/1x10&lt;sup&gt;6&lt;/sup&gt; cells</td></tr><tr><td>Acetone</td><td>Fisher</td><td>A18-1</td><td></td></tr><tr><td>Aldehyde dehydrogenase (ALDH) substrate</td><td>Stemcell Technologies</td><td>1700</td><td>Sold commerically as part of the ALDEFLOUR Assay kit; follow manufacturer&#039;s instructions for ALDH substrate preparation</td></tr><tr><td>Basement membrane extract (BME)</td><td>Corning</td><td>354234</td><td>Sold under the commercial name Matrigel</td></tr><tr><td>Cell culture plates: 6 well</td><td>Corning</td><td>877218</td><td></td></tr><tr><td>Cell culture plates: 60mm</td><td>Corning</td><td>353002</td><td></td></tr><tr><td>Cell culture plates: 96-well ultra low attachment</td><td>Corning</td><td>3474</td><td></td></tr><tr><td>Cell strainer: 40 micron</td><td>BD</td><td>352340</td><td></td></tr><tr><td>Collagen</td><td>Stemcell Technologies</td><td>7001</td><td>Prepare 1:30 dilution of 3 mg/mL collagen in PBS</td></tr><tr><td>Collagenase</td><td>Sigma</td><td>11088807001</td><td>1x</td></tr><tr><td>Conical tubes: 50 mL</td><td>Fisher scientific</td><td>05-539-7</td><td></td></tr><tr><td>Crystal violet</td><td>Sigma</td><td>C6158</td><td>Use 0.05% crystal violet solution in water for staining</td></tr><tr><td>Dispase</td><td>Stemcell Technologies</td><td>7913</td><td>5U/mL</td></tr><tr><td>DMEM:F12</td><td>Gibco</td><td>11330-032</td><td>1x, With L-glutamine and 15 mM HEPES</td></tr><tr><td>DNAse</td><td>Sigma</td><td>D5052</td><td>0.1 mg/mL final concentration</td></tr><tr><td>FBS</td><td>Avantor Seradigm Lifescience</td><td>97068-085</td><td>&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;</td></tr><tr><td>Flow tubes: 5ml</td><td>BD</td><td>352063</td><td>Polypropylene round-bottom tubes</td></tr><tr><td>Methanol</td><td>Fisher</td><td>84124</td><td></td></tr><tr><td>mouse anti-Human CD24 antibody</td><td>BD</td><td>561646</td><td>R-phycoerythrin and Cyanine dye conjugated Clone: ML5</td></tr><tr><td>mouse anti-Human CD44 antibody</td><td>BD</td><td>555479</td><td>R-phycoerythrin conjugated, Clone: G44-26</td></tr><tr><td>N,N-diethylaminobenzaldehyde (DEAB)</td><td>Stemcell Technologies</td><td>1700</td><td>Sold commerically as part of the ALDEFLOUR Assay kit; follow manufacturer&#039;s instructions DEAB preparation</td></tr><tr><td>PBS</td><td>Wisent Inc</td><td>311-425-CL</td><td>1x, Without calcium and magnesium</td></tr><tr><td>Trypsin-EDTA</td><td>Gibco</td><td>25200-056</td><td></td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>&lt;strong&gt;Mammosphere Media Composition&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>B27</td><td>Gibco</td><td>17504-44</td><td>1x</td></tr><tr><td>bFGF</td><td>Sigma</td><td>F2006</td><td>10 ng/mL</td></tr><tr><td>BSA</td><td>Bioshop</td><td>ALB003</td><td>04%</td></tr><tr><td>DMEM:F12</td><td>Gibco</td><td>11330-032</td><td>1x, With L-glutamine and 15 mM HEPES</td></tr><tr><td>EGF</td><td>Sigma</td><td>E9644</td><td>20 ng/mL</td></tr><tr><td>Insulin</td><td>Sigma</td><td>16634</td><td>5 &amp;micro;g/mL</td></tr><tr><td></td><td></td><td></td><td></td></tr><tr><td>&lt;strong&gt;3D Organoid Media Composition&lt;/strong&gt;</td><td></td><td></td><td></td></tr><tr><td>A8301</td><td>Tocris</td><td>2939</td><td>500 nM</td></tr><tr><td>B27</td><td>Gibco</td><td>17504-44</td><td>1x</td></tr><tr><td>DMEM:F12</td><td>Gibco</td><td>11330-032</td><td>1x, With L-glutamine and 15 mM HEPES</td></tr><tr><td>EGF</td><td>Sigma</td><td>E9644</td><td>5 ng/mL</td></tr><tr><td>FGF10</td><td>Peprotech</td><td>100-26</td><td>20 ng/mL</td></tr><tr><td>FGF7</td><td>Peprotech</td><td>100-19</td><td>5 ng/mL</td></tr><tr><td>GlutaMax</td><td>Invitrogen</td><td>35050-061</td><td>1x</td></tr><tr><td>HEPES</td><td>Gibco</td><td>15630-080</td><td>10 mM</td></tr><tr><td>N-acetylcysteine</td><td>Sigma</td><td>A9165</td><td>1.25 mM</td></tr><tr><td>Neuregulin &amp;beta;1</td><td>Peprotech</td><td>100-03</td><td>5 nM</td></tr><tr><td>Nicotinamide</td><td>Sigma</td><td>N0636</td><td>5 mM</td></tr><tr><td>Noggin</td><td>Peprotech</td><td>120-10C</td><td>100 ng/mL</td></tr><tr><td>R-spondin3</td><td>R&amp;amp;D</td><td>3500</td><td>250 ng/mL</td></tr><tr><td>SB202190</td><td>Sigma</td><td>S7067</td><td>500 nM</td></tr><tr><td>Y-27632</td><td>Tocris</td><td>1254</td><td>5 &amp;micro;M</td></tr></tbody></table>

isolation and functional assessment of human breast cancer stem cells from cell and tissue samples

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Breast cancer stem cells (BCSCs) are cancer cells with inherited or acquired stem cell-like characteristics. Despite their low frequency, they are major contributors to breast cancer initiation, relapse, metastasis and therapy resistance. It is imperative to understand the biology of breast cancer stem cells in order to identify novel therapeutic targets to treat breast cancer. Breast cancer stem cells are isolated and characterized based on expression of unique cell surface markers such as CD44, CD24 and enzymatic activity of aldehyde dehydrogenase (ALDH). These ALDHhighCD44+CD24- cells constitute the BCSC population and can be isolated by fluorescence-activated cell sorting (FACS) for downstream functional studies. Depending on the scientific question, different in vitro and in vivo methods can be used to assess the functional characteristics of BCSCs. Here, we provide a detailed experimental protocol for isolation of human BCSCs from both heterogenous populations of breast cancer cells as well as primary tumor tissue obtained from breast cancer patients. In addition, we highlight downstream in vitro and in vivo functional assays including colony forming assays, mammosphere assays, 3D culture models and tumor xenograft assays that can be used to assess BCSC function.

The described protocol allows isolation of human BCSCs from a heterogenous population of breast cancer cells, either from cell lines or from dissociated tumor tissue. For any given cell line or tissue sample, it is crucial to generate a uniform single cell suspension to isolate BCSCs at maximum purity as contaminating non-BCSC populations could result in variable cellular responses, especially if the study aim is to evaluate the efficacy of therapeutic agents targeting BCSCs. Application of a stringent sorting strategy w...

This experimental protocol describes the isolation of BCSCs from breast cancer cell and tissue samples as well as the in vitro and in vivo assays that can be used to assess BCSC phenotype and function.

Breast cancer stem cells (BCSCs) are cancer cells with inherited or acquired stem cell-like characteristics. Despite their low frequency, they are major ...

isolation-functional-assessment-human-breast-cancer-stem-cells-from

Research

JoVE Journal

Cancer Research

Cancer stem cells (CSCs) have been identified in a number of malignancies.  In this protocol we describe a flow cytometric method utilizing aldehyde dehydrogenase activity and CD44 and CD24 expression to isolate CSCs from human pancreatic adenocarcinoma xenografts.  These viable cells can then be used in functional and analytical studies.

Isolation of Stem Cells from Human Pancreatic Cancer Xenografts

The identification of brain tumor initiating cells (BTICs), the rare cells within a heterogeneous tumor possessing stem cell properties, provides new insights into human brain tumor pathogenesis. We have refined specific culture conditions to enrich for BTICs, and we routinely use flow cytometry to further enrich these populations. Self-renewal assays and transcript analysis by single cell RT-PCR can subsequently be performed on these isolated cells.

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting

The isolation of cancer stem cells (CSCs) directly from human tissues is requisite for their biological characterization. This manuscript describes a methodology for the isolation of prostate CSCs from human tissues, while also providing tips on troubleshooting difficult steps.

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

In vitro spheres assays are commonly used to identify cancer stem cells. Here we compare single with multi cell-based spheres assays. The more laborious single cell-based assays or methylcellulose supplementation give more accurate results while multi cell-based assays performed in liquid medium can be highly influenced by cell density.

Evaluation of Stem Cell Properties in Human Ovarian Carcinoma Cells Using Multi and Single Cell-based Spheres Assays

Floating mammosphere assays can investigate the subset of stem-like breast cancer cells that survive in suspension conditions and show enhanced tumorigenesis when implanted into mice.  This protocol provides a convenient in vitro measure of sphere-forming ability, a proxy for in vivo tumorigenesis, while facilitating analysis of the stem-associated transcriptional landscape.

Mammosphere Formation Assay from Human Breast Cancer Tissues and Cell Lines

The presence of cancer stem cells (CSCs) in bone sarcomas has recently been linked to their pathogenesis. In this article, we present the isolation of CSCs from primary cell cultures obtained from human biopsies of conventional osteosarcoma (OS) using the ability of CSCs to grow under nonadherent conditions.

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Understanding the role of cancer stem-like cells in tumor recurrence and resistance to therapies has become a topic of great interest in the last decade. This article describes the isolation and characterization of the sub-population of cancer stem-like cells from head and neck squamous carcinoma cell lines (HNSCC).

Isolation and Characterization of a Head and Neck Squamous Cell Carcinoma Subpopulation Having Stem Cell Characteristics

This procedure will demonstrate how we synthesized and characterized the anti-NFκB and anti-cancer stem cell activity of an aspirin-fumarate prodrug.

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NF&#954;B Activity and Breast Cancer Stem Cells

The aim of this methodology is to identify cancer stem cells (CSC) in cancer cell lines and primary human tumor samples with the sphere-forming protocol, in a robust manner, using functional assays and phenotypic characterization with flow cytometry and Western blot.

Obtaining Cancer Stem Cell Spheres from Gynecological and Breast Cancer Tumors

Using human primary prostate epithelial cells, we report a novel biomarker-free method of functional characterization of stem-like cells by a spheroid-based label-retention assay. A step-by-step protocol is described for BrdU, CFSE, or Far Red 2D cell labeling; three-dimensional spheroid formation; label-retaining stem-like cell identification by immunocytochemistry; and isolation by FACS.

Isolation of Stem-like Cells from 3-Dimensional Spheroid Cultures

This protocol describes the method for setting up the mammosphere formation assay to study Apoptosis Inhibitor 5 (Api5)- induced cancer stemness in non-tumorigenic breast epithelial cells. Lysates collected from primary generation mammospheres are analysed for different stemness markers to assess the induction of stem cell-like properties.

Mammosphere Assay Reveals Api5-Induced Stemness in Non-Tumorigenic Breast Epithelial Cell Lines

Learn to isolate breast cancer stem cells from cell and tissue samples with high purity and viability. This protocol enables in vitro and in vivo functional assays to study tumorigenicity and metastasis.

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Explore More Videos